MindImmune

Neuroinflammation: The Next Frontier in Alzheimer’s and Other Neurodegenerative Diseases

Rewriting Alzheimer’s: Targeting Immune Drivers of Neurodegeneration: MindImmune is shifting the paradigm in Alzheimer’s research by focusing on immune system dysfunction rather than traditional amyloid targets. The team identified a peripheral immune cell that infiltrates the brain and drives synaptic damage. To counter this, they’re advancing MITI-101, a monoclonal antibody designed to block the recruitment of these cells and potentially halt the neuroinflammatory cascade behind Alzheimer’s progression.
From Pharma to Frontier: After a distinguished career in big pharma, including leadership roles at Pfizer and Lundbeck, MindImmune Chief Science Officer, Dr. Stevin Zorn, made a pivotal shift. Frustrated by the limited impact of traditional approaches targeting brain circuitry, he co-founded MindImmune to pursue a bold new path targeting immune-driven mechanisms of neurodegeneration. Dr. Zorn and Chief Executive Officer, Isaac Stoner, are now leading a mission that could redefine how we treat Alzheimer’s disease.
2026 Milestones: Following the close of $10.2 million Series A extension in November 2025, bringing the total Series A capital raised to $30 million, MindImmune anticipates utilizing proceeds from the financing to initiate the Phase 1 clinical study of MITI-101 in 2026.